Konstantinos N. Syrigos

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Edward B. Garon, Tudor–Eliade Ciuleanu, Óscar Arrieta et al. · The Lancet · 2014 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +16

Programmed death ligand-1 expression in non-small cell lung cancer

Vamsidhar Velcheti, Kurt A. Schalper, Daniel Carvajal et al. · Laboratory Investigation · 2013 · 753 citations · Full text

Medicine, Cancer Biology, Oncology +14

Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer

Kurt A. Schalper, Jason R. Brown, Daniel Carvajal‐Hausdorf et al. · JNCI Journal of the National Cancer Institute · 2015 · 431 citations · Full text

Medicine, Immunology, Oncology +17

Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

Eleni Karapanagiotou, Victoria Roulstone, Katie Twigger et al. · Clinical Cancer Research · 2012 · 187 citations · Full text

Medicine, Oncology, Pharmacology +15

High-Plex Predictive Marker Discovery for Melanoma Immunotherapy–Treated Patients Using Digital Spatial Profiling

Maria Toki, Christopher R. B. Merritt, Pok Fai Wong et al. · Clinical Cancer Research · 2019 · 172 citations

Medicine, Immunology, Oncology +17